Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab versus apremilast for moderate plaque psoriasis in adults eligible for systemic therapy
MOH_2021-07-06_010075Phase 4Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- May 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in plaque psoriasis comparing Risankizumab, Apremilast then risankizumab and Apremilast (3 arms). Started May 2021; status: active, not recruiting.
02
Drugs
risankizumabapremilast
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on MOH_2021-07-06_010075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-07-06_010075.